ECSP067050A - Forma de dosificacion solida de heparina humeda - Google Patents

Forma de dosificacion solida de heparina humeda

Info

Publication number
ECSP067050A
ECSP067050A EC2006007050A ECSP067050A ECSP067050A EC SP067050 A ECSP067050 A EC SP067050A EC 2006007050 A EC2006007050 A EC 2006007050A EC SP067050 A ECSP067050 A EC SP067050A EC SP067050 A ECSP067050 A EC SP067050A
Authority
EC
Ecuador
Prior art keywords
heparin
wet
dosage form
solid dosage
humeda
Prior art date
Application number
EC2006007050A
Other languages
English (en)
Inventor
Shingai Majuru
Brahma Singh
Nikhil Dhoot
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of ECSP067050A publication Critical patent/ECSP067050A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica sólida (tal como una forma de dosificación sólida) que comprende un agente de suministro y heparina húmeda. La inclusión de heparina húmeda en lugar de la heparina no húmeda en la composición farmacéutica sólida resulta en la liberación aumentada de heparina. Sin vincularse por cualquier teoría particular, los solicitantes creen que debido a que la cadena de polímero de la heparina húmeda ya está en forma "abierta", mientras que la heparina no húmeda no lo está, menos de la heparina húmeda se disuelve en el aparato gastrointestinal y se absorbe más fácilmente en el estómago.
EC2006007050A 2004-05-06 2006-12-07 Forma de dosificacion solida de heparina humeda ECSP067050A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56947504P 2004-05-06 2004-05-06
US57267904P 2004-05-19 2004-05-19
US59897804P 2004-08-04 2004-08-04

Publications (1)

Publication Number Publication Date
ECSP067050A true ECSP067050A (es) 2007-02-28

Family

ID=35320730

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006007050A ECSP067050A (es) 2004-05-06 2006-12-07 Forma de dosificacion solida de heparina humeda

Country Status (14)

Country Link
US (1) US8039018B2 (es)
EP (1) EP1750729A2 (es)
JP (1) JP2007536268A (es)
KR (1) KR20070008720A (es)
AU (1) AU2005240206B2 (es)
BR (1) BRPI0510226A (es)
CA (1) CA2564866A1 (es)
EC (1) ECSP067050A (es)
IL (1) IL178846A0 (es)
MA (1) MA28774B1 (es)
MX (1) MXPA06012841A (es)
NZ (1) NZ550894A (es)
RU (1) RU2006138703A (es)
WO (1) WO2005107773A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393324T3 (es) * 2004-05-14 2012-12-20 Emisphere Technologies, Inc. Compuestos y composiciones para administrar principios activos
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
US20130150323A1 (en) * 2010-02-04 2013-06-13 Urigen Pharmaceuticals, Inc Use of oral heparin preparations to treat urinary tract diseases and conditions
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2023102690A1 (en) * 2021-12-06 2023-06-15 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of heparins

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510561A (en) 1965-05-20 1970-05-05 Canada Packers Ltd Sulfone-enhanced heparin absorption through mucous membranes
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5541155A (en) 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US6916489B2 (en) 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20040062773A1 (en) 1993-04-22 2004-04-01 Emisphere Technologies Inc. Compositions for the delivery of antigens
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1997047288A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
WO1998021951A1 (en) 1996-11-18 1998-05-28 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
EP1059941B1 (en) 1998-03-05 2004-05-26 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
US6949816B2 (en) * 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
AU751612B2 (en) 1998-07-27 2002-08-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
IL140930A0 (en) 1998-08-07 2002-02-10 Emisphere Tech Inc Compounds and compositions for delivering active agents
JP2002534363A (ja) 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2000047188A1 (en) 1999-02-11 2000-08-17 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
MXPA02004092A (es) 1999-11-05 2003-02-12 Emisphere Tech Inc Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
AU1594801A (en) 1999-11-12 2001-06-06 Emisphere Technologies, Inc. Liquid heparin formulation
EP1237872B1 (en) 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4879433B2 (ja) 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6384278B1 (en) 2000-02-04 2002-05-07 Emisphere Technologies, Inc. Boron-mediated amidation of carboxylic acids
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
JP4799794B2 (ja) 2000-03-21 2011-10-26 エミスフェアー・テクノロジーズ・インク ジカルボキシル化中間体を介してアルキル化サリチルアミドを調製する方法。
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
NZ523017A (en) 2000-06-29 2004-10-29 Emisphere Tech Inc Compounds and compositions for delivering active agents and preparation method thereof
EP1317412A1 (en) 2000-08-18 2003-06-11 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2002015959A2 (en) 2000-08-18 2002-02-28 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001296865A1 (en) 2000-09-06 2002-03-22 Emisphere Technologies, Inc. (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
JP5089845B2 (ja) 2000-09-06 2012-12-05 エミスフェアー・テクノロジーズ・インク シアノフェノキシカルボン酸化合物および活性薬剤送達用組成物
CN1494420A (zh) 2001-03-01 2004-05-05 埃米斯菲尔技术公司 释放活性成分的化合物和组合物
US20030225300A1 (en) 2001-04-19 2003-12-04 Emisphere Technologies Inc. Compounds and compositions for delivering active agents
MXPA05012278A (es) 2003-05-14 2006-02-10 Emisphere Tech Inc Composiciones para suministrar peptido yy y combatientes pyy.

Also Published As

Publication number Publication date
MA28774B1 (fr) 2007-08-01
MXPA06012841A (es) 2007-02-15
US20070224262A1 (en) 2007-09-27
KR20070008720A (ko) 2007-01-17
WO2005107773A2 (en) 2005-11-17
JP2007536268A (ja) 2007-12-13
BRPI0510226A (pt) 2007-10-23
RU2006138703A (ru) 2008-06-20
NZ550894A (en) 2011-02-25
AU2005240206A1 (en) 2005-11-17
CA2564866A1 (en) 2005-11-17
WO2005107773A3 (en) 2006-01-05
AU2005240206B2 (en) 2011-04-07
US8039018B2 (en) 2011-10-18
EP1750729A2 (en) 2007-02-14
IL178846A0 (en) 2007-05-15
WO2005107773A8 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
EP2200573A4 (en) COMPOUNDS OF RESVERATROLFERULAT, COMPOSITIONS CONTAINING THESE COMPOUNDS, AND APPLICATION METHODS THEREWITH
CL2009000404A1 (es) Compuestos derivados de piperidin-indol-sustituidos, moduladores de receptores nociceptina/orl1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del snc, cardiovasculares, metabolicas, entre otras.
WO2009089338A3 (en) Method and compositions for administering resveratrol and pterostilbene
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
CL2008003016A1 (es) Composicion para tratamiento de lavanderia que comprende una base de tratamiento de lavanderia y desde 0,01 a 10% en peso de particulas de film laminar concavas coloreadas.
PT2079456E (pt) Composições farmacêuticas de ciclosporina
EP2413693A4 (en) SUBSTITUTED AZOANTHRENE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREFOR AND METHOD OF USE THEREOF
CL2009001560A1 (es) Composición nutricional para bebes que comprende una mezcla de oligosacáridos compuesta de oligosacáridos n-acetilados, galactooligosácaridos y oligosacáridos sialilados; y su uso.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
HN2008000188A (es) 7- aza- indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y su utilizacion
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
EP2123734A4 (en) BENZIMIDAZOLE CONTAINING COMPOSITION AND ILLUMINATING AGENT THEREOF
BRPI0819051A2 (pt) Composição de resina, película e bolsa de retorta
TR201905480T4 (tr) Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
CL2007003154A1 (es) Compuestos derivados de pirazolina; composicion farmaceutica que comprende a los compuestos; y uso para tratar afecciones cardiovasculares, renales, hepaticas y vasculares entre otras.
AR070105A1 (es) Composicion de detergente para lavanderia que comprende un glicosilo hidrolasa y un agente benefico que contiene particulas de suministro
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
BRPI0519741A2 (pt) composição de cuidado oral, e, método para clareamento de uma superfìcie de dente
EP2119752A4 (en) INDOOR COMPOSITION COMPOSITION AND LIGHTING APPARATUS USED BY THE COMPOSITION
MX2008011846A (es) Procedimiento para preparar una composicion de caucho, composicion de caucho obtenida del mismo, y uso del mismo.
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
EP2322574A4 (en) IONOMIC RESIN, RESIN COMPOSITIONS AND THE USE OF BOTH
ECSP099611A (es) Composiciones farmaceuticas que comprenden un agente calcilitico